Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products.The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes.
Its wearable device offers personalized and transdermal nicotine replacement therapy in combination with real-time behavioral support.CTI provides nicotine replacement therapy which is delivered through the skin without needles or injection.
The company also offers re-usable base device and replaceable cartridges.It provides pre-clinical trial, scientific support and clinical research services.
The company markets its products across the US. CTI is headquartered in Hayward, California, the US.
Chrono Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The global liquid biopsy market is expected to reach nearly US$ 6.5 Billion by 2026. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. The abilities of liquid biopsy like, easy and minimal invasiveness, early cancer diagnosis & detection, characterization...
Transplant Complications Drug Development Pipeline Review, 2018 Summary GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient’s body. Symptoms include abdominal pain or cramps, nausea, vomiting,...
The global demand for Otitis Media treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Otitis Media pipeline. Companies quickly adapting to the change and moving their products to advanced...
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018 Summary According to the recently published report ’Wilms Tumor Protein - Pipeline Review, H2 2018’; Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed...
Retinopathy Of Prematurity - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2018, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape. Retinopathy...
Glomerulonephritis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2018, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape. Glomerulonephritis...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.